Types of fiscal rules
Effects of fiscal rules on government spending
When is a technology cost-effective?
If the ICER is below the monetary threshold it is cost effective, if it is above it is not cost effective
absolute shortfall
disease - related health loss
proportional shortfall
(disease - related health loss) / remaining health expectations in absence of disease
fair innings
fair innings is the only severity approach that takes past health into account
two arguments in fair innings
Why proportional shortfall?
Normative justification:
* Health technologies for more severely ill patients are more necessary
* Combines aspects of severity and fair innings approaches (past health disregarded)
* Balances concerns about discrimination based on age in reimbursement decisions (proportional shortfall is 1 in case of immediate death at all ages)
Equity weighting based on age
(Explicit) equity weighting based on age in economic evaluations is not allowed, but:
* Using QALYs in economic evaluations may prioritize younger patients (they have more potential QALYs to gain than older patients, so ICER more likely to be <vi)
* Prospective health and rule of rescue may prioritize older patients (they have less remaining QALYs than younger patients)
* Absolute shortfall may prioritize younger patients (they have more remaining QALYs left to lose than older patients)
* Proportional shortfall may prioritize older patients (they are more likely to lose a larger proportion of their remaining QALYs, e.g., in case of chronic illnesses).
Rationing in tax-funded healthcare system
Tax-funded healthcare acts are enforced by the government and and implemented by municipalities.
Government responsible for:
* Allocation of fixed budget to municipalities based on objective distribution key (supply-side rationing)
* Determining level of co-payments (demand-side rationing)
Municipalities (344 in March 2022) responsible for:
* (Timely) access to customized, high-quality care
* Early signalling of care needs
Rationing in insurance-based healthcare system
Insurance-based healthcare acts are enforced by the government and implemented by policymakers, health insurers and healthcare providers.
Long Term Care Act (Wlz):
* Mandatory income-based premium (≥ 15 years); fixed percentage (~10%) of income on a maximum gross income of ~€34,000
* Demand-side rationing:
o Access based on needs (re-) assessment by the Care Assessment Agency (CIZ) and availability of informal care
o Income-dependent copayment: accounts for differences in price sensitivity between SES groups and ensures access for lower income groups
Health Insurance Act (Zvw):
* Mandatory for everyone of >= 18 years
* Broad coverage of curative healthcare services
* Insurance companies obliged to accept anyone at same premium and contract competing care providers
* Healthcare allowance for lower income groups
Focus on demand-side rationing:
* Mandatory deductible of €385; voluntary deductible of +€500 against premium rebate of €240
* Demarcation of basic benefits package by National Health Care Institute (ZIN)
ZIN advises the Ministry of Health, Welfare and Sport on the demarcation of the basic benefits package on the basis of four decision criteria:
Open system
Concerns specialist inpatient (pharmaceutical) care:
* Automatically included in basic benefits package if it meets the “medical science and practice” criterion
Since 2018:
* Expensive new pharmaceuticals are not automatically included in basic benefits package, but labelled “in transit” (in Dutch: “de sluis”) when:
o Costs are ≥ €50,000 per treatment per year and ≥ €10 million per year in total, or:
o Costs are ≥ €40 million per year in total, irrespective of costs per treatment
* Only included after price negotiations (ZIN advises Ministry of Health, Welfare and Sport on price reduction that is necessary to meet the cost-effectiveness criterion)
Closed system
Concerns outpatient (pharmaceutical) care:
* ZIN advises Minister of Health on inclusion in basic benefits package
Pharmaceuticals reimbursed if included in Drug Reimbursement System (GVS):
* Annex 1a –> Clustering of interchangeable pharmaceuticals
o Reimbursement limit
o Co-payment (max €250 per year) for pharmaceuticals that are above limit
* Annex 1b Unique pharmaceuticals
o Fully reimbursed
o Move to annex 1a when pharmaceuticals become interchangeable
* Annex 2 –> Unique or expensive pharmaceuticals (overlap annex 1a and 1b)
o Reimbursement if certain conditions are met (e.g., only reimbursed for specific subgroup)
Assessment phase
Appraisal phase
Public involvement
Policymakers increasingly seek ways to (also) involve members of the public in reimbursement decisions, with the objective to:
* Actively involve the public in shaping new policies that affect their lives
* Better align outcomes and process of decision making with societal preferences
* Increase legitimacy of and societal support for decisions on rationing healthcare
berekening incremental costs
costs new treatment - costs standard care
berekening incremental QALY gain
effects new treatment - effects standard care
berekening incremental cost-effectiveness ratio
incremental costs / incremental QALY gain
Efficiency arguments